Trending

immunology

J&J filing aims Tremfya at crowded psoriatic arthritis market

J&J filing aims Tremfya at crowded psoriatic arthritis market

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication,

X

J&J filing aims Tremfya at crowded psoriatic arthritis market

https://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/

FDA agrees to downsized trial for Calliditas’ rare disease drug

FDA agrees to downsized trial for Calliditas’ rare disease drug

The FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease,

X

FDA agrees to downsized trial for Calliditas’ rare disease drug

https://pharmaphorum.com/news/fda-agrees-to-downsized-trial-for-calliditas-rare-disease-drug/

Amgen stumps up $13.4bn to claim Otezla from Celgene

Amgen stumps up $13.4bn to claim Otezla from Celgene

Celgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen

X

Amgen stumps up $13.4bn to claim Otezla from Celgene

https://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/

Sobi cuts staff and buys Novimmune drug in refocus

Sobi cuts staff and buys Novimmune drug in refocus

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst

X

Sobi cuts staff and buys Novimmune drug in refocus

https://pharmaphorum.com/news/sobi-cuts-staff-novimmune-drug-refocus/

Merck bolts on another immunology firm with $773m Tilos deal

Merck bolts on another immunology firm with $773m Tilos deal

Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its

X

Merck bolts on another immunology firm with $773m Tilos deal

https://pharmaphorum.com/news/merck-bolts-on-another-immunology-firm-with-773m-tilos-deal/

CAR-Ts – a new weapon in the fight against cancer

CAR-Ts – a new weapon in the fight against cancer

CAR-T – or Chimeric Antigen Receptor T-cell therapies herald a new wave of therapies in cancer. CAR-T therapies

X

CAR-Ts – a new weapon in the fight against cancer

https://pharmaphorum.com/views-and-analysis/car-ts-a-new-weapon-in-the-fight-against-cancer/

Novartis pays up to $1 billion for potential eczema drug

Novartis pays up to $1 billion for potential eczema drug

Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to

X

Novartis pays up to $1 billion for potential eczema drug

https://pharmaphorum.com/news/novartis-increases-its-immunology-footprint-with-1-billion-deal/

Roche to buy rest of genetics firm Foundation Medicine

Roche to buy rest of genetics firm Foundation Medicine

Roche has made an offer to buy the remaining shares in cancer genetics firm Foundation Medicine (FMI) for

X

Roche to buy rest of genetics firm Foundation Medicine

https://pharmaphorum.com/news/roche-buys-shares-foundation-medicine/

More good news for AbbVie in rheumatoid arthritis

More good news for AbbVie in rheumatoid arthritis

AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.

X

More good news for AbbVie in rheumatoid arthritis

https://pharmaphorum.com/news/abbvie-rheumatoid-arthritis/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com